endovascular
(4)
Evident Vascular, Inc.
Evident Vascular is a San Jose-based medical device startup building an AI-powered intravascular ultrasound (IVUS) platform designed for peripheral vascular interventions. Founded in 2023 and led by CEO Howard Rosen, the company aims to fix the long-standing trade-off between image quality and clinical workflow that has limited IVUS adoption, targeting FDA 510(k) clearance ahead of a U.S. launch. It raised a $35M Series A from Vensana Capital and closed an undisclosed Series B in 2025.
Inquis Medical, Inc.
Inquis Medical is a Silicon Valley medical device company founded in 2020 by serial medtech entrepreneurs Vahid and Mojgan Saadat. Its flagship AVENTUS Precision Thrombectomy System removes blood clots from patients with pulmonary embolism (PE) and deep vein thrombosis (DVT), using proprietary TrueClot tissue-sensing technology that gives physicians real-time feedback to distinguish blood, clot, and vessel wall while minimizing blood loss through autologous blood reinfusion. Backed by $115M in total funding including a $75M Series C in January 2026, the company is scaling nationwide commercial adoption after winning FDA 510(k) clearance for PE in 2025.
InterVene, Inc.
InterVene, Inc. is a Redwood City, California vascular medical device company building catheter-based tools for severe venous disease. Born out of Stanford Biodesign, it first pioneered BlueLeaf, a non-implantable system that forms new vein valves from a patient's own tissue, then pivoted its lead product to Recana, an FDA-cleared thrombectomy catheter system that clears venous in-stent restenosis and native-vessel obstructions - a stubborn problem that leaves stented patients with debilitating complications and few good options.
NeuroBionics
NeuroBionics is a Boston-area neurotechnology company spun out of more than a decade of MIT research. It builds hair-thin, flexible bioelectronic fibers that reach neural targets through the body's blood vessels instead of open surgery. Its lead device, evStim, aims to deliver deep brain and peripheral nerve stimulation endovascularly, potentially widening access to neuromodulation therapy for conditions like Parkinson's disease, epilepsy, chronic pain, and depression.